BioPharma Resources

Drug Trial Radar · NCT06065748

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,050 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,050

Planned (sponsor's estimate)

Start

Dec 11, 2023

Primary completion

Apr 20, 2028

Study completion Feb 12, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.

Conditions

  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Interventions

  • GiredestrantDrug

    Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.

  • FulvestrantDrug

    Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.

  • AbemaciclibDrug

    If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.

  • PalbociclibDrug

    If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.

  • RibociclibDrug

    If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.

  • LHRH AgonistDrug

    Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.

  • FoundationOne Liquid CDx Assay (F1LCDx)Diagnostic test

    F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) in the ESR1 mutation (ESR1m) SubgroupTime frame: From randomization to first occurrence of progressive disease (PD) or death (up to 5 years)
  2. PFS in the Full Analysis Set (FAS) PopulationTime frame: From randomization to first occurrence of PD or death (up to 5 years)

Locations

311 sites in 37 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Daphne, Alabama

  • Marin Cancer Care Inc

    Greenbrae, California

  • Kaiser Permanente - Harbor City

    Harbor City, California

  • Oncura Health

    Los Angeles, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente

    Torrance, California

  • Rocky Mountain Cancer Centers

    Littleton, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • MedStar Washington Hosp Center

    Washington D.C., District of Columbia

  • AdventHealth Altamonte

    Altamonte Springs, Florida

  • Florida Cancer Specialists - Broadway

    Fort Myers, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg)

    St. Petersburg, Florida

  • Comprehensive Hematology Oncology

    St. Petersburg, Florida

  • Florida Cancer Specialists - EAST - SCRI - PPDS

    West Palm Beach, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Baptist Health Louisville

    Louisville, Kentucky

  • New England Cancer Specialists

    Scarborough, Maine

  • Maryland Oncology Hematology

    Annapolis, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • HCA Midwest Division

    Kansas City, Missouri

  • Oncology Hematology West - Grand Island

    Grand Island, Nebraska

  • Oncology Hematology West - Legacy

    Omaha, Nebraska

  • Astera Cancer Care East Brunswick

    East Brunswick, New Jersey

  • Duke Women Cancer Care

    Raleigh, North Carolina

  • Asante Rogue Regional Medical Center

    Medford, Oregon

  • Alliance Cancer Specialists

    Bensalem, Pennsylvania

  • Ann B. Barshinger Cancer Institute

    Lancaster, Pennsylvania

  • Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit

    Philadelphia, Pennsylvania

  • Brown University Health

    Providence, Rhode Island

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • West Cancer Center

    Germantown, Tennessee

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Texas Oncology Cancer Center

    Austin, Texas

  • Texas Oncology - DFW

    Irving, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Virginia Commonwealth University - Massey Cancer Center

    Richmond, Virginia

  • Northwest Medical Specialties

    Tacoma, Washington

  • West Virginia University Hospitals Inc

    Morgantown, West Virginia

Showing 40 of 311 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.